Eyenovia Appoints Michael Rowe as VP of Marketing as Late-Stage Pipeline Advances


NEW YORK—Eyenovia Inc. (NASDAQ: EYEN), a clinical stage biopharmaceutical company, has named Michael Rowe as vice president of marketing, according to an announcement this week. Eyenovia is developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the U.S. and globally across the health care industry. Before joining Eyenovia, he was head of global strategic marketing, ophthalmology, at Aerie Pharmaceuticals Inc.

At Aerie, he was responsible for the U.S. and international commercialization, planning and execution for Rhopressa, for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Rowe also spent 12 years at Allergan plc in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort UD, according to the Eyenovia announcement. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First Healthcare Inc. and Pfizer Inc.

Dr. Sean Ianchulev, chief executive officer of Eyenovia, said in the announcement that as “Eyenovia advances its late-stage pipeline, we believe Michael can help us further develop our marketing strategy and focus our commercial efforts. We believe his extensive experience leading the strategic direction for the commercialization of various products at Aerie, Allergan and Bayer can help us realize our vision to transform the ophthalmic space.”

Rowe said he believes Eyenovia’s micro-therapeutic approach and diverse late-stage pipeline has “the ability to offer the field of ophthalmology a novel and sophisticated way to treat patients with front and back-of-the-eye conditions. With the potential to commercialize two new products for mydriasis and dry eye in the next 18 months, as well as initiate phase III trials in myopia and chronic angle-closure glaucoma by mid-2019, I look forward to working with the team on developing and executing a robust commercialization plan that can help lead Eyenovia’s success.”

Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases, according to the company’s announcement.